Cancer researchers studying 44 known genetic variants associated with breast cancer have found the way to identify why they increase cancer risk, opening the door to future therapeutic applications based on personalized medicine. The findings, published online September 24 ahead of print in Nature Genetics, fill a gap that will expand the reach of genetic profiling beyond merely screening, says principal investigator Dr. Mathieu Lupien, a scientist at Ontario Cancer Institute, the research arm of the Princess Margaret Cancer Centre at University Health Network. Dr. Lupien, who specializes in epigenetics in cancer, is also an Assistant Professor in the Department of Medical Biophysics, University of Toronto.
